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complications, irreversible failure, non-eligibility and death. Transition probabilities 
between health states were obtained from results of published clinical trials. Costs 
included in the model comprised those associated with surgery, patients’ follow up
and post-surgical complications. Speciﬁ cally, costs related to visits to physician, medi-
cations as well as those incurred at the hospital were included in the model. Number 
of QALYs was estimated pre and post-surgery using the EQ-5D questionnaire from
patients undergoing PK or lamellar surgery at Maisonneuve Rosemont Hospital (Mon-
treal, Qc). RESULTS: The lamellar keratoplasty techniques were proved to be more 
effective, providing more QALYs (43 QALYs / 100 patients), and were less costly 
(50,437 CD$ / 100 patients) compared to PK. The gain of QALYs associated with 
lamellar keratoplasty resulted from a reduction of the waiting time for transplantation 
and from lower postoperative complication rates, both related to poor utility values. 
Deterministic and probabilistic sensitivity analyses conﬁ rmed the robustness of the
base-case results. CONCLUSIONS: From a clinical and an economic standpoint, 
lamellar keratoplasty represents a preferred strategy for the treatment of corneal 
endothelial diseases.
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OBJECTIVES: Implantation of toric intraocular lens (IOL) corrects preexisting astig-
matism in cataract patients, providing better clinical outcomes compared to conven-
tional monofocal IOLs. We sought to assess the impact of these clinical outcomes on 
lifetime patient health-related quality of life (HRQL) and economic outcomes.
METHODS: A clinically based economic model examined outcomes in cataract 
patients q 65 years old with pre-existing astigmatism (1.5–3D). Subjects received either
bilateral toric IOLs or conventional IOLs, with or without intra-operative refractive 
correction for astigmatism. Data obtained from a systematic literature review were
supplemented with survey results from 60 United States cataract and refractive sur-
geons. A prospective study provided data translating uncorrected visual acuity (UCVA) 
to patient utilities. Outcomes were projected over life time and discounted at 3%.
RESULTS: The proportion of patients achieving spectacle independence and UCVA q
20/25 with toric IOL was greater (67% and 53%) than that with conventional IOL
with (63% and 48%) or without (53% and 44%) intra-operative refractive correction.
Due to better UCVA outcomes, Toric IOL resulted in better utility scores than con-
ventional IOL with and without intra-operative refractive correction. This utility gain,
coupled with a reduced lifetime likelihood of wearing glasses and contact lenses
resulted in toric IOL being the dominant strategy over conventional IOL without
intra-operative refractive correction. The use of toric IOL resulted in the total lifetime
cost saving of $336/QALY. CONCLUSIONS: Toric IOLs improve patients’ HRQL
by providing better vision outcomes and reduction in the need for intra- and post-
operative refractive correction in cataract patients with astigmatism thus reducing the 
risks associated with refractive surgery. Other than visual acuity, additional factors 
should be considered by physicians and patients for the initial choice of treatment: 
the inconvenience of travel with glasses, lens cleaning and intangible beneﬁ ts associ-
ated with improved self-perception.
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OBJECTIVES: Burn patients undergoing skin graft ﬁ xation utilize additional health
care resources with removal of staples (RoS). The objective of this study was to report
time and resources utilized during RoS. METHODS: Data were extracted from a
phase three multi-center clinical trial assessing efﬁ cacy and safety of a ﬁ brin sealant 
(FS) compared to staples. Subjects had burn wounds measuring 40% of total body
surface area (TBSA) and study wound sites measured 1–4% of TBSA. Health resource
assessment included number of staples, number of visits to remove staples, time to
remove staples, number of health care personnel removing staples, and additional pain 
medication. RESULTS: A total of 127 patients were included in this analysis. Of those,
66% were male and 69% were white. The median age was 29 years (range 1–62 
years). The median number of staples used for skin grafting was 30 (range 7–88). One
visit was required (Range 1–2), utilizing 10 minutes (Range 1–365) to remove staples.
A median of 2 health care professionals were involved (range 1–9). A total of 59%
of patients received additional sedation/pain medication during staple removal. The
mean number of medications administered was 1.4 (range 1–3), and the most common
choices were midazolam  fentanyl, morphine, or ketamine. CONCLUSIONS:
Removal of staples requires additional medical resources that can be quantiﬁ ed in 
terms of costs. Comprehensive cost-beneﬁ t analyses are needed to compare total cost
of care by method of graft ﬁ xation.
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OBJECTIVES: Long-term treatment with 0.1% tacrolimus ointment (TO) has been 
demonstrated as well-tolerated and effective for the treatment of atopic dermatitis (AD)
but its impact on utility has not been reported. The purpose of this study was to esti-
mate utility changes associated with TO versus a standard corticosteroid regimen (CR)
in the treatment of moderate-to-severe AD in adults. METHODS: Data were analysed 
from a double-blind RCT. Patients were treated with either TO applied twice-daily for 
six months to the head, neck, trunk and extremities, or alternatively 0.1% hydrocorti-
sone butyrate ointment administered to the trunk and extremities and 1% hydrocorti-
sone acetate ointment applied to the head and neck. Health-related utility (EQ5Dindex)
was estimated by Monte Carlo simulation from SF12 responses collected during the 
clinical trial by applying a published mapping algorithm. RESULTS: Data were avail-
able for 972 patients (intention-to-treat), 46% of whom were male with a mean age of 
32 years (SD 12). At baseline the mean EQ5Dindex was similar between both arms 
(0.721 vs. 0.730; p  0.461, for CR vs. TO, respectively). After 28 days the mean
EQ5Dindex improved in both treatment arms (0.820 vs. 0.849; p  0.004, respectively).
The incremental EQ5Dindex between the treatment arms increased as the trial pro-
gressed. At 6-months subjects treated with TO had signiﬁ cantly higher utility than 
CR-treated subjects (0.789 vs. 0.831; p  0.001; respectively). CONCLUSIONS:
Patients with AD had considerable decrement in health-related utility at baseline. Treat-
ment with 0.1% tacrolimus ointment was associated with a consistently improved, 
clinically-signiﬁ cant, incremental increase in health-related utility compared to the 
corticosteroid regimen, increasing over a six month period.
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OBJECTIVES: Progressive vision loss caused by retinopathy is a common and debili-
tating effect of diabetes. Standardized descriptions of the functional impacts of diabetic 
retinopathy are required to develop health state descriptions for eliciting utilities. The
objective was to characterize the functional impacts of diabetic retinopathy according
to levels of visual function, informing relevant health states in diabetic retinopathy.
METHODS: A list of potentially important impacts was developed from the literature
and the National Eye Institute Visual Function Questionnaire (VFQ). One-on-one 
qualitative interviews were then conducted with 30 subjects with diabetic retinopathy 
to solicit feedback on functional and activity limitations. All participants underwent 
Early Treatment of Diabetic Retinopathy Study visual acuity and contrast sensitivity 
testing. A thematic analysis characterized the nature and drivers of functional limita-
tions in diabetic retinopathy. Health state descriptions using these parameters were 
developed and reviewed by three ophthalmologists and one endocrinologist. RESULTS:
Qualitative interviewing identiﬁ ed that visual acuity and contrast sensitivity in the 
better- and worse-seeing eyes, the difference in these measures between the eyes, and
the ability to drive were important determinants of health status. These status indica-
tors were highly associated with participation in leisure activities; reading ﬁ ne print 
(important for maintaining glycemic control when reading nutritional labels or glu-
cometers); seeing well at a distance; and mobility outside the home. Functional limita-
tions less useful in distinguishing between individuals with different visual functioning
levels included watching television and needing help from others. Eleven unique health 
states, deﬁ ned by visual acuity, contrast sensitivity, and VFQ scores, were then devel-
oped which can be used for estimating vision-related utilities in diabetic retinopathy. 
CONCLUSIONS: This is the ﬁ rst study to categorize the vision-speciﬁ c functional
impacts of diabetic retinopathy according to measures of vision function. Measuring
health state utilities for diabetic retinopathy is now feasible using these health state 
descriptions.
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OBJECTIVES: To explore how driving status and bilateral visual acuity (best-eye 
(BEVA) and worst-eye (WEVA)) impact quality of life (QOL) in patients with NV-
ARMD in terms of health utility (HU) derived from the EuroQol (EQ-5D) and QOL
derived from the National Eye Institute Vision Function Questionnaire (NEI-VFQ 25).
METHODS: This cross-sectional data (n  154) at screening from a phase I/II clinical 
trial in patients with NV-ARMD was conducted in 4 countries. Patients were stratiﬁ ed 
into 4 severity groups (BEVA, 20/40; WEVA, 20/200). Four driving statuses were
extracted from NEI-VFQ 25 questions 15a and 15b, including current drivers (D),
